



Patient Information

Co-pay Savings

Physician Information

Contact Merz

Prescribing Information

## **Twice as Strong Half as Long**

#1 Topical Antifungal Brand Prescribed by Dermatologists and Podiatrists<sup>1</sup>



#### Indication

NAFTIN<sup>®</sup> (naftifine hydrochloride) Cream 2% is an allylamine antifungal indicated for the treatment of interdigital tinea pedis, tinea cruris, and tinea corporis caused by the organism *Trichophyton rubrum* in adult patients ≥18 years of age.

#### **Important Safety Information**

In clinical trials with NAFTIN<sup>®</sup> Cream 2%, the most common adverse reaction (≥1%) was pruritus.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit <a href="https://www.fda.gov/medwatch">www.fda.gov/medwatch</a> or call 1-800-FDA-1088.

Also available: NAFTIN® Gel 1%

Reference: 1. IMS Health, NPA June 2012.

NAFTIN®
(Naftifine Hydrochloride) Cream, 29

About Us | Terms of Use | Privacy Policy | Contact Us

NAFTIN is a registered trademark of Merz Pharmaceuticals, LLC. All other trademarks are the property of their respective owners. © 2013 Merz Pharmaceuticals, LLC. All rights reserved. July 2013

This site is intended for US residents only.







Patient Information

Co-pay Savings

Physician Information

Contact Merz

Prescribing Information

Twice as Strong, Half as Long

Clinical Efficacy in Tinea Cruris

Clinical Efficacy in Tinea Pedis

#### Physicians:

Order samples and request coupons for your patients.



- Once a day for 2 weeks
- Fungicidal for the most common dermatophyte
- · Clinically significant efficacy
- 14 vs 28 applications
- Improvement in results continues 2-4 weeks after treatment<sup>1,2</sup>
- Available in a 45-gram tube—ideal for 2-week treatment
- Proven safety established from naftifine hydrchloride for over 20 years<sup>3</sup>
- Many eligible patients pay \$0 co-pay for NAFTIN<sup>®</sup> Cream 2%<sup>4\*</sup>

# More than 90% of patients were able to adhere to the full course of treatment 12

<u>Download a Merz Pharmaceuticals Co-pay Savings Card</u> for your patients

\* Restrictions apply. Subject to eligibility. Please see the actual Merz Pharmaceuticals Co-pay Savings Card for complete details.

There is no generic equivalent for NAFTIN® (naftifine HCI) Cream 2%.

#### Indication

NAFTIN<sup>®</sup> (naftifine hydrochloride) Cream 2% is an allylamine antifungal indicated for the treatment of interdigital tinea pedis, tinea cruris, and tinea corporis caused by the organism *Trichophyton rubrum* in adult patients ≥18 years of age.

#### **Important Safety Information**

In clinical trials with NAFTIN<sup>®</sup> Cream 2%, the most common adverse reaction (≥1%) was pruritus.

References: 1. Parish LC, Parish JL, Routh HB, et al. A double-blind, randomized, vehicle-controlled study evaluating the efficacy and safety of naftifine 2% cream in tinea cruris. *J Drugs Dermatol*. 2011;10(10):1142-1147.

2. Parish LC, Parish JL, Routh HB, et al. A randomized, double-blind, vehicle-controlled efficacy and safety study of naftifine 2% cream in the treatment of tinea pedis. *J Drugs Dermatol*. 2011;10(11):1282-1288.

3. Data on file. Merz Pharmaceuticals.



Twice as Strong

This site is intended for US residents only.





Patient Information

Co-pay Savings

Physician Information

Contact Merz

Prescribing Information

Twice as Strong, Half as Long

Clinical Efficacy in Tinea Cruris

Clinical Efficacy in Tinea Pedis


#### Physicians:


Order samples and request coupons for your patients.

## Deliver clinically significant efficacy to tinea cruris<sup>1</sup>

Significantly greater complete cure rate (primary efficacy endpoint) at Week 4, NAFTIN® (naftifine HCI) Cream 2% (25%) vs vehicle (3%), P<0.001<sup>1\*</sup>

### In tinea cruris, at Week 4 (2 weeks post-treatment) (n=146)<sup>1</sup>:







#### **Tinea Cruris**



Tinea Pedis



greater clinical success vs vehicle at Week 4, NAFTIN® Cream 2% (84%) vs vehicle (10%), (P<0.001, n=146)<sup>1§</sup>

**Study design:** randomized, double-blind, vehicle-controlled, multicenter, 4-week study in 146 subjects with tinea cruris, comparing Naftin<sup>®</sup> Cream 2% (n=75) to vehicle (n=71) at Week 4 following a 2-week treatment for tinea cruris.<sup>1</sup>

- Complete cure is a composite endpoint of both mycological cure and clinical cure. Clinical cure is
  defined as the absence of erythema, pruritus, and scaling (score of 0 on a 4-point scale).
- † Mycological cure is defined as negative KOH and dermatophyte culture.
- ‡ Treatment effectiveness is defined as negative KOH and dermatophyte culture, and erythema, scaling, and pruritus scores of 0 and 1.
- \$ Clinical success is defined as absence or near absence of erythema, pruritus, and scaling (score of 0 or 1 on a 4-point scale).

There is no generic equivalent for NAFTIN® (naftifine HCI) Cream 2% Physicians: Order samples for your office

Also available: NAFTIN® Gel 1%

#### Indication

NAFTIN® (naftifine hydrochloride) Cream 2% is an allylamine antifungal indicated for the treatment of interdigital tinea pedis, tinea cruris, and tinea

corporis caused by the organism *Trichophyton rubrum* in adult patients ≥18 years of age.

#### **Important Safety Information**

In clinical trials with NAFTIN® Cream 2%, the most common adverse reaction ( $\geq$ 1%) was pruritus.

**Reference: 1.** Parish LC, Parish JL, Routh HB, et al. A double-blind, randomized, vehicle-controlled study evaluating the efficacy and safety of naftifine 2% cream in tinea cruris. *J Drugs Dermatol.* 2011;10(10):1142-1147.

About Us | Terms of Use | Privacy Policy | Contact Us

NAFTIN is a registered trademark of Merz Pharmaceuticals, LLC. All other trademarks are the property of their respective owners. © 2013 Merz Pharmaceuticals, LLC. All rights reserved. July 2013









Patient Information

Co-pay Savings

**Physician Information** 

Contact Merz

Prescribing Information

Twice as Strong, Half as Long

Clinical Efficacy in Tinea Cruris

Clinical Efficacy in Tinea Pedis

#### Physicians:


Order samples and request coupons for your patients.

#### Deliver clinically significant efficacy to interdigital tinea pedis


Significantly greater complete cure rate (primary efficacy endpoint) at Week 6, NAFTIN® (naftifine HCI) Cream 2% (18%) vs vehicle (7%), P<0.011\*


#### In interdigital tinea pedis at Week 6 (4 weeks post-treatment) (n=217)1:

Complete Cure'



Mycological Cure<sup>†</sup>





Tinea Cruris



**Tinea Pedis** 



greater clinical success vs vehicle at Week 6, NAFTIN® Cream 2% (78%) vs vehicle (49%), (two-sided P<0.001, n=217)19

Study design: randomized, double-blind, vehicle-controlled, multicenter, 6-week study in 217 subjects with tinea pedis, comparing NAFTIN® Cream 2% (n=147) to vehicle (n=70) at Week 6 following a 2-week treatment for tinea pedis.

- \* Complete cure is a composite endpoint of both mycological cure and clinical cure. Clinical cure is defined as the absence of erythema, pruritus, and scaling (score of 0 on a 4-point scale).
- † Mycological cure is defined as negative KOH and dermatophyte culture.
- ‡ Treatment effectiveness is defined as negative KOH and dermatophyte culture, and erythema, scaling, and pruritus scores of 0 and 1.
- § Clinical success is defined as absence or near absence of erythema, pruritus, and scaling (score of 0 or 1 on a 4-point scale).

There is no generic equivalent for NAFTIN® (naftifine HCI) Cream 2% Physicians: Order samples for your office

Also available: NAFTIN® Gel 1%

#### Indication

NAFTIN® (naftifine hydrochloride) Cream 2% is an allylamine antifungal indicated for the treatment of interdigital tinea pedis, tinea cruris, and tinea corporis caused by the organism *Trichophyton rubrum* in adult patients ≥18 years of age.

#### **Important Safety Information**

In clinical trials with NAFTIN® Cream 2%, the most common adverse reaction ( $\geq$ 1%) was pruritus.

Reference: 1. Parish LC, Parish JL, Routh HB, et al. A randomized, double-blind, vehicle-controlled efficacy and safety study of naftifine 2% cream in the treatment of tinea pedis. *J Drugs Dermatol.* 2011;10(11):1282-1288

About Us | Terms of Use | Privacy Policy | Contact Us


NAFTIN is a registered trademark of Merz Pharmaceuticals, LLC. All other trademarks are the property of their respective owners. © 2013 Merz Pharmaceuticals, LLC. All rights reserved. July 2013

This site is intended for US residents only.



Banner Size 160x60

# Twice as Strong Half as Long



# CNAFTIN CREAM 2% (Nattifine HCI) Once a day for 2 weeks

#### Indication

NAFTIN® (naftifine hydrochloride) Cream 2% is an allylamine antifungal indicated for the treatment of interdigital tinea pedis, tinea cruris, and tinea corporis caused by the organism *Trichophyton rubrum* in adult patients ≥18 years of age.

Visit www.NAFT!N.com for full Prescribing Information.

#### Banner Size 300x250 Option 1

